Psychedelics researchers welcome Trump's executive order to fast-track their work

President Trump’s April executive order aims to accelerate the testing and approval of psychedelic therapies, signaling a shift in how these substances are viewed for mental health treatment. The administration pledged at least $50 million to spur research and asked the Department of Health and Human Services to pair state investments with federal funds. The FDA issued national priority vouchers to two companies studying psilocybin for treatment-resistant depression and major depressive disorder, and a third for methylone related to PTSD. The move does not reclassify psychedelics or lift all barriers, but it signals growing openness to their potential.

Dr. Jerry Rosenbaum, director of the Center for the Neuroscience of Psychedelics at Massachusetts General Hospital, welcomed the step as a catalyst for research hindered by Schedule 1 restrictions. He noted that even transporting a psilocybin dose within a hospital requires extensive oversight, illustrating why reclassification would ease studies. Massachusetts scientists hope to share in the funding, with Dana-Farber Cancer Institute researchers exploring psychedelic-assisted therapy for cancer-related distress.

Early results suggest potential benefits, especially for depression and distress in serious illness, but researchers urge rigorous trials and careful monitoring. The funding and policy move are viewed as a modest but important step toward broader acceptance of psychedelic research within medical science.